Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer
Open Access
- 1 January 2019
- Vol. 4 (3) , e000488
Abstract
Background Nivolumab showed a survival benefit for advanced gastric cancer (AGC). However, an acceleration of tumour growth during immunotherapy, (hyperprogressive disease, HPD) has been reported in various cancers. This study reviewed the HPD in patients with AGC treated with nivolumab or irinotecan. Methods The subjects of this retrospective study were patients with AGC with measurable lesions, and their tumour growth rates (TGR) during nivolumab or irinotecan were compared with those during prior therapy. HPD was defined as an increase in TGR more than twofold. Results 34 and 66 patients received nivolumab and irinotecan in third or later line between June 2009 and September 2018 at our hospital; 22 patients receiving nivolumab had prior treatment with irinotecan, and one patient received irinotecan after nivolumab. Nivolumab and irinotecan showed no differences in disease control rates (38.2% and 34.8%) and in progression-free survival (PFS) (HR 1.1, 95% CI 0.7 to 1.6, p=0.802). The incidence of HPD was slightly higher after nivolumab (29.4%) than after irinotecan (13.5%) (p=0.0656), showing no differences in background between the patients with and without HPD. Compared between HPD and PD other than HPD after nivolumab, the HRs for PFS and overall survival (OS) were 1.1 (95% CI 0.5 to 2.7; p=0.756), and 2.1 (95% CI 0.7 to 5.8; p=0.168), but such clear difference in OS was not observed after irinotecan. Conclusions HPD was observed more frequently after nivolumab compared with irinotecan, which was associated with a poor prognosis after nivolumab but not so clearly after irinotecan.Keywords
This publication has 35 references indexed in Scilit:
- Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical TrialsClinical Cancer Research, 2014
- Management of gastric cancer in Asia: resource-stratified guidelinesThe Lancet Oncology, 2013
- Induction, control, and plasticity of Treg cells: The immune regulatory network revised?European Journal of Immunology, 2013
- PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible ChemokinesCancer Research, 2012
- Tumour growth rates and RECIST criteria in early drug developmentEuropean Journal of Cancer, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunityCancer and Metastasis Reviews, 2010
- PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCVJournal of Clinical Investigation, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000